Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

@inproceedings{Fan2014LowDoseDC,
  title={Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report},
  author={Hui Fan and Xuechun Lu and Xiaohui Wang and Yang Liu and Bo Guo and Yan Zhang and Wenying Zhang and Jing Nie and Kaichao Feng and Meixia Chen and Yajing Zhang and Yao Wang and Fengxia Shi and Xiaobing Fu and Hong-Li Zhu and Weidong Han},
  booktitle={Journal of immunology research},
  year={2014}
}
  • Hui Fan, Xuechun Lu, +13 authors Weidong Han
  • Published in
    Journal of immunology…
    2014
  • DOI:10.1155/2014/371087
Aberrant DNA methylation is one of the main drivers of tumor initiation and progression. The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies. Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some clinical benefits in patients with refractory advanced tumors; however, they are extremely toxic. Low doses of decitabine minimize toxicity while potentially improving the targeted effects of DNA… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma

Qian Mei, Meixia Chen, +5 authors Weidong Han
  • Oncotarget
  • 2015
VIEW 11 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 66 REFERENCES

X

M. Sang, X. Wu
  • Fan et al., “Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer,” Biomarkers, vol. 19, no. 1, pp. 34–42
  • 2014
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

F

D. K. Krishnadas, L. Bao
  • Bai et al., “Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1,” Tumor Biology
  • 2014
VIEW 1 EXCERPT

Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer.

  • Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • 2014

and A

A. Gomes, M. Reis-Silva
  • Alarcao, “Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung,” Revista Portuguesa de Pneumologia, vol. 20, no. 1, pp. 20–30
  • 2014

C

L. M. Kopp, A. Ray
  • J. Denman et al., “Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions,”Molecular Immunology, vol. 54, no. 3-4, pp. 296–301
  • 2013

DNAmethyltransferase inhibitors and their emerging role in epigenetic therapy of cancer

T. K. Kelly, D. D. de Carvalho, P. A. Jones
  • Anticancer Research
  • 2013